TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Integer Holdings Corp (ITGR)

Healthcare Medical Devices
121.20 $
+20.2% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Integer Holdings Corp.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 11 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
100.90$
Open
100.90$
Day High
123.50$
Day Low
99.50$
Volume
2,607,199shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
63.30 $ 121.20 $
10/30/2025 07/31/2026

Current price 121.20 $ — 100% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
4.2$B
Shares Outstanding
34Mio.
Float
98.5%
Beta
0.6

Performance

Perf. 1M
1.30%
Perf. 3M
6.90%
Perf. 6M
15.90%
YTD Performance (%)
14.20%
52-Week-High Distance
-24.8%
Perf. 1Y
11.70%
Perf. 3Y
31.07%
Perf. 5Y
23.82%
Perf. 10Y
445.75%
Perf. Since Inception
481.57%

Technical Indicators

MA 38 Days
94.90$
MA 50 Days
93.80$
MA 200 Days
85.00$
RSI (14)
83.5
Volatility 30 Days
59.8%
Volatility 250 Days
51.6%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
30.1
Forward P/E
26.0
PEG
3.2
P/B
2.4
P/S
2.3
EV/EBITDA
16.8
Price/FCF
41.8

Profitability

Gross Margin
26.8%
EBIT Margin
8.2%
Net Margin
7.6%
Return on Equity
8.6%
Return on Assets
4.2%

Balance Sheet & Safety

Equity Ratio
49.7%
Debt/Equity
0.8
fortress balance sheet
Altman Z″
6.74
Piotroski
7 out of 9

Growth

Sales Growth Last Quarter
0.50%
EPS Growth Last Quarter
52.90%
Sales Growth (Year)
7.57%
Forward Sales Growth
5.95%
Forward EPS Growth
11.90%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
31
EPS Rating
78
Piotroski
7 out of 9
Fundamental Rating
C (50 out of 100)
fortress balance sheet
Altman Z″
6.74

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

4 of 10 Weak growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 11.5% failed
  • More than 10% revenue growth is expected for the coming year 6.0% failed
  • Share count grows by less than 3% a year 2.2% passed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 13.3% failed
  • Gross margin at 40% or higher and without meaningful erosion 23.1% failed
  • Goodwill from acquisitions does not grow faster than revenue 32.6% passed
  • Net debt below twice EBITDA 4.7 x EBITDA failed
  • Operating cash flow covers the profits of the last three years 268 m passed
  • Return on capital at 15% or higher, or up versus two years ago 6.6% passed
  • Insiders hold at least 10% or are net buyers 1.4% failed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 121.20 $
Price Target (average) 101.20 $

The price target sits 16.5% below the current price.

Consensus
Strong Sell
Analyst Ratings
10
Distribution of Recommendations
Strong Buy 7
Buy 2
Hold 1
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 6.08 5.90 – 6.20 1,817 -4.9% 10
12/31/2027 6.82 6.49 – 6.96 1,925 12.1% 9

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

6. Aug 2026 · before the open · Q2 2026
Expected Earnings per Share
1.38 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 449.5 $M Q4 2025: Q1 · 436.2 $M Q1 2025: Q2 · 472.8 $M Q2 2025: Q3 · 466.6 $M Q3 2025: Q4 · 470.9 $M Q4 2026: Q1 · 439.6 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.90 16.40 450 11.10 7.30 63 44
2025: Q1 -0.66 -213.40 436 7.00 -5.20 31 6
2025: Q2 1.04 17.80 473 10.50 7.80 44 25
2025: Q3 1.11 12.50 467 8.10 8.50 66 46
2025: Q4 1.38 53.30 471 4.80 10.30 55 28
2026: Q1 0.48 440 0.80 3.80 25 1
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 1,076 93 6 0.19 106 725 2,833
2017 1,136 126 67 2.08 149 893 2,848
2018 1,215 156 168 5.15 167 1,060 2,327
2019 1,258 158 96 2.92 165 1,152 2,353
2020 1,073 121 77 2.33 181 1,271 2,372
2021 1,221 136 97 2.91 157 1,355 2,582
2022 1,331 113 66 1.99 116 1,417 2,794
2023 1,556 163 91 2.69 180 1,519 2,943
2024 1,717 208 120 3.36 205 1,619 3,078
2025 1,846 209 103 2.89 196 1,747 3,411

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Integer Holdings Corporation ist als Auftragsentwicklungs- und -fertigungsunternehmen für Medizinprodukte in den USA, Costa Rica, Puerto Rico, Irland und international tätig. Das Unternehmen bietet Produkte für interventionelle Kardiologie, strukturelle Herzerkrankungen, Herzinsuffizienz, periphere Gefäße, n…

CEO Insider Trades (12 Mo.)buying own stock
Employees11,000
HeadquartersPlano, TX
Address5830 Granite Parkway, 75024 Plano, United States
Phone214 618 5243
Websiteinteger.net
IPO Date29. Sep 2000
ISINUS45826H1095

Management

Management
Name Title Birth Year
Payman Khales CEO, President & Director 1970
Diron Smith Executive VP & CFO 1974
Lindsay Krause Blackwood J.D. Senior VP, General Counsel, Chief Ethics & Compliance Officer and Corporate Secretary 1977
Jim Stephens Executive Vice President of Special Projects 1974
Tom P. Thomas VP, Corporate Controller & Principal Accounting Officer 1971
Carol Russell VP & Chief Information Officer
Kristen Marie Stewart C.F.A. Director of Investor Relations
Kirk K. Thor Ph.D. Executive VP & Chief Human Resources Officer 1964
Sanjiv Arora Senior Vice President of Strategy, Business Development and Investor Relations 1966
Tony Carr Executive Vice President of Global Quality & Regulatory Affairs 1979

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?